Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Lonsurf + irinotecan + bevacizumab in unresectable metastatic colorectal cancer
jRCTs061180069Phase 1Active, not recruiting
- Start
- Oct 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of trifluridine + tipiracil, irinotecan and bevacizumab in colorectal cancer (CRC), Colon adenocarcinoma and rectal adenocarcinoma. Primary endpoint: Recommended dose (RD). Started Oct 2015; status: active, not recruiting.
02
Drugs
trifluridine + tipiracilirinotecanbevacizumab
03
Conditions
colorectal cancer (CRC)Colon adenocarcinomarectal adenocarcinoma
Beyond the preview
Go deeper on jRCTs061180069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061180069.